This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: PARTNER II

December 2016 Br J Cardiol 2016;24:41 Online First

News from the AHA Scientific Sessions 2016

BJCardio Staff

Abstract

PIONEER: rivaroxaban and antiplatelets reduce bleeding in AF post-PCI A combination of two different strategies of the non-vitamin K oral antagonist, rivaroxaban, plus either mono or dual antiplatelet therapy (DAPT), significantly reduced the risk of clinically significant bleeding compared to standard triple therapy in patients with atrial fibrillation after percutaneous coronary intervention (PCI). PIONEER AF PCI (Two Treatment Strategies of Rivaroxaban and a Dose-adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with Atrial Fibrillation who Undergo Percutaneous Coronary Intervention) was an open-label, randomised, controll

| Full text

For healthcare professionals only

Add Banner

Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now